Expanding Uses of Fluoroquinolones: Opportunities and Challenges
Authors: David C. Hooper
Journal: Annals of Internal Medicine (1998)

Editorials1 December 1998Expanding Uses of Fluoroquinolones: Opportunities and ChallengesDavid C. Hooper, MDDavid C. Hooper, MDMassachusetts General Hospital; Boston, MA 02114-2696Note: Dr. Hooper has received investigator-initiated grant support from several manufacturers of quinolone antibiotics and has served on advisory boards for other companies that make these products.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Drugs in the quinolone or related naphthyridine class have been available since the 1960s. Nalidixic acid, the first agent of the class to be used clinically, was largely limited to treatment of urinary tract infections. The mid-1980s saw the introduction of newer, more potent, fluorinated quinolones with broader spectra of activity and broader applications for treatment of bone, joint, and systemic infections and infections of the genital, gastrointestinal, and respiratory tracts [1]. Of the five fluoroquinolones introduced in the United States by 1992, ciprofloxacin and ofloxacin were most widely used because they had the greatest potency and the broadest set ...References1. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991; 324:384-94. Google Scholar2. Hooper DC, Wolfson JS. Norfloxacin, ciprofloxacin, and ofloxacin: current clinical roles. Curr Clin Top Infect Dis. 1989; 10:194-240. Google Scholar3. Two new fluoroquinolones [Letter]. Med Lett Drugs Ther. 1992; 34:58-60. Google Scholar4. Grepafloxacin-a new fluoroquinolone [Letter]. Med Lett Drugs Ther. 1998; 40:17-8. Google Scholar5. Trovafloxacin [Letter]. Med Lett Drugs Ther. 1998; 40:30-1. Google Scholar6. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis. 1998; 26:811-38. Google Scholar7. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis. 1997; 29:249-57. Google Scholar8. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med. 1994; 331:377-82. Google Scholar9. Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995; 333:474-80. Google Scholar10. Ortqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. Chest. 1996; 110:1499-506. Google Scholar11. File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997; 41:1965-72. Google Scholar12. Langan CE, Cranfield R, Breisch S, Pettit R. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother. 1997; 40(Suppl A):63-72. Google Scholar13. Stein GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis. 1996; 23(Suppl 1):S19-24. Google Scholar14. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA. 1997; 278:901-4. Google Scholar15. Solomkin JS, Reinhart HH, Dellinger EP, Bohnen JM, Rotstein OD, Vogel SB, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg. 1996; 223:303-15. Google Scholar16. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis. 1991; 163:1279-85. Google Scholar17. Carratala J, Fernandez-Sevilla A, Tubau F, Dominguez MA, Gudiol F. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother. 1996; 40:503-5. Google Scholar18. Dudley MN. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med. 1991; 91:45S-50S. Google Scholar19. Hooper DC, Wolfson JS. Mechanisms of bacterial resistance to quinolones. In: Hooper DC, Wolfson JS, eds. Quinolone Antimicrobial Agents. 2d ed. Washington, DC: American Society for Microbiology; 1993; 97-118. Google Scholar20. Low DE, Scheld WM. Strategies for stemming the tide of antimicrobial resistance [Editorial]. JAMA. 1998; 279:394-5. Google Scholar Author, Article, and Disclosure InformationAuthors: David C. Hooper, MDAffiliations: Massachusetts General Hospital; Boston, MA 02114-2696Note: Dr. Hooper has received investigator-initiated grant support from several manufacturers of quinolone antibiotics and has served on advisory boards for other companies that make these products.Corresponding Author: David C. Hooper, MD, Infectious Disease Division, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114-2696; e-mail, [email protected] PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMolecular Evolution of the Pseudomonas aeruginosa DNA Gyrase gyrA GeneImpact of biochar on plant growth and uptake of ciprofloxacin, triclocarban and triclosan from biosolidsFluoroquinolones: Blessings Or CursesCiprofloxacin transformation in aqueous environments: Mechanism, kinetics, and toxicity assessment during •OH-mediated oxidationEffects of subinhibitory ciprofloxacin concentrations on the abundance of qnrS and composition of bacterial communities from water supply reservoirsFluoroquinolonesRelevance of fluoroquinolone use in a French teaching hospitalToxic effect of the combined antibiotics ciprofloxacin, lincomycin, and tylosin on two species of marine diatomsRecent advances in the analysis of antibiotics by CE and CECEffect of ciprofloxacin on microbiological development in wetland mesocosmsANTIBACTERIAL DRUGSIn Tepid Defense of Population Health: Physicians and Antibiotic ResistanceNational and Regional Assessment of Antimicrobial Resistance among Community-Acquired Respiratory Tract Pathogens Identified in a 2005-2006 U.S. Faropenem Surveillance StudyThe Eye in the WildernessProspective assessment of fluoroquinolone use in a teaching hospitalPlasmid Profiles of Multidrug Resistant Local Uropathogenic Escherichia coli, Klebsiella spp., Proteus spp. and Pseudomonas spp. IsolatesLack of effect of fluoroquinolone resistance on mortality in subjects with Pseudomonas aeruginosa bacteraemiaFluoroquinolonesCoadministration of oral levofloxacin with agents that impair its absorption: potential impact on emergence of resistanceFluoroquinolone prescribing in the United States: 1995 to 2002High Rate of Coadministration of Di- or Tri-valent Cation-Containing Compounds With Oral Fluoroquinolones: Risk Factors and Potential ImplicationsBlood Culture and Susceptibility Results and Allergy History Do Not Influence Fluoroquinolone Use in the Treatment of Community-Acquired PneumoniaRecurrent tendinitis after treatment with two different fluoroquinolonesGatifloxacin in community-acquired respiratory tract infectionFactors Associated with Relative Rates of Antimicrobial Resistance among Streptococcus pneumoniae in the United States: Results from the TRUST Surveillance Program (1998–2002)Antibiotic Prescribing Decisions of Generalists and Infectious Disease Specialists: Thresholds for Adopting New Drug TherapiesTensions in antibiotic prescribingOnce daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trialA Nosocomial Outbreak of Fluoroquinolone‐Resistant Streptococcus pneumoniaeUsefulness of Betalactam Therapy for Community-Acquired Pneumonia in the Era of Drug-Resistant Streptococcus pneumoniae: A Randomized Study of Amoxicillin-Clavulanate and CeftriaxoneAcute Exacerbations of Chronic BronchitisAntimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999)Use of the Quinolones in Immunocompromised PatientsPapel de las nuevas fluoroquinolonas en las infecciones respiratorias en atención primariaFluoroquinolone Resistance in Streptococcus pneumoniaeNew concepts in antimicrobial therapy for emergency department infectionsFluoroquinolone Resistance in Streptococcus pneumoniaeMatthew J. Kuehnert, MD, Frederick S. Nolte, PhD, and Carl A. Perlino, MDTreatment options for resistant pneumococcal infectionsDecreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada 1 December 1998Volume 129, Issue 11_Part_1Page: 908-910KeywordsAntibioticsAttentionBacterial pneumoniaDrugsPathogensPenicillinPneumoniaRespiratory system proceduresStreptococcusUpper respiratory tract infections ePublished: 15 August 2000 Issue Published: 1 December 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...